Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Beat $714.290 Estimate. Cash And Equivalents $164.9M
Portfolio Pulse from Benzinga Newsdesk
Altimmune (NASDAQ:ALT) reported Q2 2024 GAAP EPS of $(0.35), missing the $(0.34) estimate, and sales of $5.000K, beating the $714.290K estimate. Cash and equivalents stand at $164.9M.
August 08, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Altimmune reported a Q2 2024 GAAP EPS of $(0.35), missing the $(0.34) estimate, and sales of $5.000K, significantly beating the $714.290K estimate. Cash and equivalents are $164.9M.
While Altimmune missed EPS estimates by a small margin, the significant beat on sales estimates and strong cash position may offset the negative sentiment. The stock price impact is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100